MDxHealth SA (MDXH)
| Market Cap | 104.78M |
| Revenue (ttm) | 107.88M |
| Net Income (ttm) | -33.52M |
| Shares Out | 51.36M |
| EPS (ttm) | -0.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 97,789 |
| Open | 2.020 |
| Previous Close | 2.040 |
| Day's Range | 2.020 - 2.090 |
| 52-Week Range | 1.670 - 5.330 |
| Beta | -537,510.36 |
| Analysts | Strong Buy |
| Price Target | 7.67 (+275.98%) |
| Earnings Date | May 14, 2026 |
About MDXH
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company’s testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient’s previously biopsied negative tissue; and Resolve mdx for urinary tract infection that identifies pe... [Read more]
Financial Performance
In 2025, MDxHealth's revenue was $107.88 million, an increase of 19.80% compared to the previous year's $90.05 million. Losses were -$33.52 million, -11.95% less than in 2024.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for MDXH stock is "Strong Buy." The 12-month stock price target is $7.67, which is an increase of 275.98% from the latest price.
News
Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026
Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026
MDxHealth Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw strong revenue growth, driven by the ExoDx integration and balanced expansion across tissue and liquid biopsy segments. 2026 guidance targets 28% revenue growth and a 10% EBITDA margin, supported by disciplined capital allocation and operational efficiencies.
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 Company to Host Conference Call with Live Q&A, February 26, 2026, at 4:30pm ET / 22:30 CET ...
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer
MDxHealth Earnings Call Transcript: Q3 2025
Q3 revenue grew 18% year-over-year to $27.4M, with strong gross margin and positive adjusted EBITDA. The ExoDx acquisition expanded the test menu and salesforce, offsetting the exit from germline and SelectMDx, while 2025 revenue guidance remains unchanged at $108–$110M.
Angle PLC Announces Strategy Update
Appointment of Executive Chairman, proposed change of name and strategy update Company to pursue revised strategy and name change to CelLBxHealth plc Dr. Jan Groen, the current Non-Executive Chairman ...
MDxHealth Earnings Call Transcript: Q2 2025
Q2 2025 saw 20% revenue growth to $26.6M and the first positive adjusted EBITDA. The pending ExoDx acquisition is expected to accelerate growth, be accretive to EBITDA, and contribute over $20M in revenue in 2026, with further details post-closing.
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne
M dxh ealth Reports Preliminary Second Quarter 202 5 Results , Reaches Positive Adjusted EBITDA , and A nnounces Acquisition of Exo some D iagnostics B usiness from Bio - Techne
Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change
IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment o...
MDxHealth Earnings Call Transcript: Q1 2025
Q1 2025 delivered 22% revenue growth and 41% tissue-based test volume growth, with gross margin rising to 63.8%. The company reaffirmed 2025 guidance, expects positive Adjusted EBITDA in Q2, and continues to see strong adoption of its diagnostic menu among urology and pathology groups.
MDxHealth Reports Q1-2025 Results
Year-over-year Q1 revenues increase by 22% to $24.3 million 71% year-over-year improvement in adjusted EBITDA in first quarter Conference call with Q&A today at 4:30 PM ET / 22:30 CET
MDxHealth Earnings Call Transcript: Q4 2024
Q4 and full year 2024 revenue grew 28% with strong test volume gains and improved profitability metrics. 2025 guidance targets $108–$110 million in revenue and adjusted EBITDA positivity in the first half, with continued leverage from existing sales channels and a robust balance sheet.
Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results
Fourth quarter revenue growth of 28% to $24.7 million 2024 revenue growth of 28% to $90.0 million 68% improvement in adjusted EBITDA in fourth quarter Conference call with Q&A today at 4:30 PM EST / 2...
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance IRVINE, CA – January 13, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or ...
MDxHealth Transcript: Piper Sandler 36th Annual Healthcare Conference
Diagnostic test volumes have rebounded, driving over 20% organic growth, especially in tissue-based tests. Menu expansion and commercial execution support sustainable growth, with further opportunities in urology and adjacent cancers. Gross margin and cost controls position the business for EBITDA break-even in early 2025.
MDxHealth to Participate in Piper Sandler Healthcare Conference
MDxHealth to Participate in Piper Sandler Healthcare Conference IRVINE, CA – November 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnos...
MDxHealth Earnings Call Transcript: Q3 2024
Q3 2024 saw 21% revenue growth and raised full-year guidance to $87–$89 million, driven by strong test volume increases and robust adoption in urology diagnostics. Cash position was strengthened by a $40M equity raise, and management projects sustainable 20%+ annual growth.
MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024
Tissue-based test volumes increase by 36%, liquid-based test volumes by 24% Company raises 2024 revenue guidance to $87-89 million, representing 25% growth Pro-forma cash of $53.5 million Conference c...
MDxHealth Announces Pricing of Offering of Ordinary Shares
MDxHealth Announces Pricing of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM – September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company“), a commerc...
MDxHealth Announces Launch of Offering of Ordinary Shares
MDxHealth Announces Launch of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM –September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company”), a commercia...
MDxHealth Earnings Call Transcript: Q2 2024
Q2 2024 revenue grew 32% year-over-year to $22.2M, driven by strong test volume and menu expansion. Gross margin held at 60%, and 2024 revenue guidance was raised to $85–$87M, reflecting confidence in sustainable growth and new test launches.
MDxHealth Reports Q2 and Half Year 2024 Results
MDxHealth Reports Q2 and Half Year 2024 Results Year-over-year Q2 revenues increase by 32% to $22.2 million Year-over-year H1 revenues increase by 34% to 42.0 million Conference call with Q&A today at...
MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21
MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21 Company to Host Conference Call with Live Q&A, August 21, 2024, at 4:30pm ET / 22:30 CET IRV...
MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance
MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a commercia...